Private and Confidential
CRB Bio II: A New Investment
Opportunity in Biotech
November, 2010
A Unique Spanish Biotech Initiative
A new Venture Capital Fund specialized in early stage investment in the
biotechnology ...
 The new Fund is anchored on six differential competitive advantages to generate
high financial returns
3
A Unique Spanis...
P. 4
Enrique Castellón – CEO & Chairman
PhD in Medicine, Economist. Former Secretary of State for Health and Consumers in
...
Cross Road Biotech: a history of success
0
5
10
15
20
25
30
35
2002 2003 2004 2005 2006 2007 2008 2009 2010
Evolution of a...
Current portfolio. Companies
P. 6 - Cross Road Biotech SCR - Confidential Information
LACTEST
• Test for lactose intoleran...
Current portfolio. Companies
P. 7 - Cross Road Biotech SCR - Confidential Information
EMBRYOMICS
• The aim is to improve a...
Current portfolio. Companies
P. 8 - Cross Road Biotech SCR - Confidential Information
NLIFE / DENDRICO
• nLife Therapeutic...
Current portfolio. Equity Position
Services Products DivestmentSe
LIVER DISEASES AND
METABOLOMICS
41,7%
(2006)
(2009)
(201...
The Management Team of CRB promotes the creation of a
new Venture Capital Firm named CRB Inverbío
 The partners and found...
Outline of the Transition
Managing
Team
CRB SCR
Managing
Team
Current
CRB
portfolio
BIO II
Fund
Other
Funds
Venture Capita...
Vision and Mision of the new BIO II Fund
• Vision
The most profitable Spanish fund specialized in life sciences at initial...
Strategy and magnitudes of the new Bio II Fund
• Name: CRB Bio II Fund
• Size of Fund: €60 M first close November 2010
• D...
Investment Strategy will look for a balanced portfolio
 Technology and field of operation
• The investment strategy manda...
Timing for the incorporation of the Fund
15
2Q 3Q 4Q 1Q 2Q
2010
Venture Capital Investment Firm
incorporation (CRB Inverbí...
Almagro 1, 1º derecha
28010 Madrid, Spain
Tel.: +00 34 91 446 7897
Email: info@crbinverbio.com
Web: www.crossroadbiotech.c...
Upcoming SlideShare
Loading in...5
×

Crb Bio Ii Summary Nov2010 Eng

627
-1

Published on

Brief presentation of new Biotech VC Fund promoted by CRB Inverbio

Published in: Economy & Finance, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
627
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Crb Bio Ii Summary Nov2010 Eng

  1. 1. Private and Confidential CRB Bio II: A New Investment Opportunity in Biotech November, 2010
  2. 2. A Unique Spanish Biotech Initiative A new Venture Capital Fund specialized in early stage investment in the biotechnology sector with a target fund size of €60 million.  The Fund will be managed by a new Venture Capital Firm (CRB Inverbío) created by the founding partners of Cross Road Biotech, a Spanish venture capital company with wide experience and track record in biotech project management.  Cross Road Biotech currently has a diversified portfolio of eleven companies in the biomedicine sector at different stages of development.  Cross Road Biotech has achieved a unique know how in the Spanish venture capital market specialized in biotechnology and its portfolio will generate net returns several times higher than the investment. Cross Road Biotech SCR - Confidential InformationP. 2
  3. 3.  The new Fund is anchored on six differential competitive advantages to generate high financial returns 3 A Unique Spanish Biotech Initiative Experience and track record in continuous value creation in the biotech industry Deep scientific understanding and extensive network of contacts Experienced Management Team with high credibility, led by Enrique Castellón Proven capacity to access non dilutable funds as a way of leveraging investments Hands on involvement in the management and divestment strategy, adding value from the first moment Leadership position in a growing sector in Spain allowing CRB to attract and generate proprietary operations Cross Road Biotech SCR - Confidential Information
  4. 4. P. 4 Enrique Castellón – CEO & Chairman PhD in Medicine, Economist. Former Secretary of State for Health and Consumers in the Health and Consumer Ministry. Chairman of the Spanish Medicines' Agency. Creation of national oncological research centers (CNIO) and cardiovascular disease centers (CNIC). Deputy minister for Health and Social Services in the region of Madrid . General Manager of the health service of Galicia Pablo Cabello – Technical and Scientific Director Molecular Biologist. Professional experience in the Instituto de Biología Celular. Histopathology services in the Fundación Jiménez Diaz Hospital. 20 years in the Molecular Genetics laboratory of the Hospital Ramón y Cajal. Executive Team - Founding partners Manuel Castellón – Managing Director. Lawyer and Economist. Master in Legal Counselling. 25 years of experience as corporate lawyer . Director and certified company counsel in various companies including Antena 3 Radio and Grupo Prisa. Founder of Castellón Abogados. Founding Team of CRB Inverbío Cross Road Biotech SCR - Confidential Information Angel Santos – Director of Business Development Engineer. Has developed his career in Spain, the UK and the US in companies such as Johnson's Wax and Lilly, in which he has held different leadership positions in general management, strategic and corporate development, M&A, business development and innovation management.
  5. 5. Cross Road Biotech: a history of success 0 5 10 15 20 25 30 35 2002 2003 2004 2005 2006 2007 2008 2009 2010 Evolution of assets under management CRB Capital Increase 11 Companies +€32M invested 82 job creation 38 patents P. 5 Cross Road Biotech SCR - Confidential Information CRB has demonstrated capacity identifying and developing biotechnology companies in the human health sector, creating value for shareholders
  6. 6. Current portfolio. Companies P. 6 - Cross Road Biotech SCR - Confidential Information LACTEST • Test for lactose intolerance which is able to measure the level of intolerance of the patient • Overcomes the deficiencies of current systems. Simple production, rapid evaluation of results. TCD PHARMA • Platform with therapeutical compounds and prognostic solutions for treating different types of cancer, using an innovative and technically viable approach to the diseases. • The approach is based on new therapeutical targets such as Choline Kinase and the development of potential inhibitors. GREEN MOLECULAR • A technology platform of naturally occuring polyphenols with multiple indications in huge prevalence areas. • Anti-tumoral and anti-metastasic in high incidence cancer types: colorrectal and malignant melanoma. Also anti-inflamatory, anti-aging and dermo protection.
  7. 7. Current portfolio. Companies P. 7 - Cross Road Biotech SCR - Confidential Information EMBRYOMICS • The aim is to improve and simplify the pre-implantational analysis that determine the viability and absence of some illnesses in human reproduction treatments. • This advance will be a step forward compared to the previous methods of diagnostic, avoiding the use of invasive procedures. OWL GENOMICS • A biotechnology company that develops new diagnostic systems and therapeutic targets based on metabolomics. • The company has identified Steatosis and NASH biomarkers that compound a metabolomic signature with diagnostic value that is being first introduced in the Spanish Hospital market. BIOCROSS • Non-invasive serum based diagnostic test for Alzheimer´s disease which overcomes the unreliability of current clinical evaluations. • The test is designed to be used to discriminate Alzheimer´s from other types of dementia.
  8. 8. Current portfolio. Companies P. 8 - Cross Road Biotech SCR - Confidential Information NLIFE / DENDRICO • nLife Therapeutics is a discovery-stage biopharmaceutical company using the development and potential commercialization of proprietary therapeutics based on RNA interferences and DNA vaccines for the treatment of human diseases. • The nanotherapeutics company is focused on major depression disorders, obesity and a new generation of vaccines for influenza. NEOCODEX • NeoCodex is working with leading global pharmaceutical, government and academic institutions in the design and implementation of new biomarker studies. The company owns patents on genetic markers related to cardiovascular risk, osteoporosis and reproductive abnormalities. • The company is bringing together the best of biomaterials and innovative genomic analysis methods to the world of genomic discovery, diagnostics and drug development. GENOMADRID • Diagnostic test for detecting the proviral charge of HIV to allow a better monitoring of the disease. • The kit will enable the forecasting of the evolution and to determine the continuity termination or suspension of the treatment for HIV patients.
  9. 9. Current portfolio. Equity Position Services Products DivestmentSe LIVER DISEASES AND METABOLOMICS 41,7% (2006) (2009) (2013) LACTOSE INTOLERANCE 51,4% (-) (2009) (2010) FARMACOGENOMICS 4,5% (2006) (2007) (2010) ALZHEIMER DIAGNOSTICS 90,8% (-) (-) (2011) siRNA THERAPEUTICAL APPLICATIONS NANOTECHNOLOGY DRUG DELIVERY ONCOLOGY 63,4% (-) (2011) (2013) VIH DIAGNOSTICS 99,7% (-) (2010) (2010) ONCOLOGY 74,9% (-) (-) (2013) PREIMPLANTATIONAL DIAGNOSIS CRB 5% OWL 30% (2010) (2011) (2014) 100% (-) (-) (2010) 50% (-) (-) (2014) P. 9 Cross Road Biotech SCR - Confidential Information
  10. 10. The Management Team of CRB promotes the creation of a new Venture Capital Firm named CRB Inverbío  The partners and founders of CRB have achieved a unique know how in the Spanish venture capital market specialized in biotechnology.  The constitution of a new fund promoted by the Venture Capital Firm will give continuity to CRB´s entrepreneurial initiative.  There are many new projects with great potential that can be consider into the new structure of CRB Inverbío.  CRB Inverbío fills in a market segment that does not count with other parties, which represents an opportunity for accessing proprietary investments and thus, a competitive advantage.  There is an increasing interest from the regional and local governments and institutions in promoting specialized investment vehicles in biotechnology.  CRB Inverbío is well positioned to be the reference partner to this initiatives. P. 10 Cross Road Biotech SCR - Confidential Information
  11. 11. Outline of the Transition Managing Team CRB SCR Managing Team Current CRB portfolio BIO II Fund Other Funds Venture Capital Firm P. 11 Cross Road Biotech SCR - Confidential Information New Projects
  12. 12. Vision and Mision of the new BIO II Fund • Vision The most profitable Spanish fund specialized in life sciences at initial stages, developing business projects based on new scientific solutions that cover unmet medical and or technological needs. • Mision  To select the best business projects based on advanced science and technology and with great opportunities for value creation.  To guarantee the best development, financing and strategic management until the clinic or industrial proof of concept that maximizes the value equation.  Divest with added value that will assure big returns to the investors. P. 12 Cross Road Biotech SCR - Confidential Information
  13. 13. Strategy and magnitudes of the new Bio II Fund • Name: CRB Bio II Fund • Size of Fund: €60 M first close November 2010 • Duration: 8 years (+2) • Investment period: 3 years (+1) • Minimum investment: Depending upon project needs • Maximum investment: up to 15% of the fund • Follow-on Investment paced in multiple rounds upon milestone achievement • Number of investments: 10-12 • Investment outside Spain: max 10% • Investment in biomedicine: up to 80% • Investment in med tech: up to 10% • Investment in other life sciences: up to 20% 13 Cross Road Biotech SCR - Confidential Information
  14. 14. Investment Strategy will look for a balanced portfolio  Technology and field of operation • The investment strategy mandates the majority of the Fund to be invested in the biomedicine field as this is the area where CRB has developed its expertise and know how. • However the new Fund will extend its reach and consider investments in closely related fields of operations and technologies including: – Agriculture and Animal health – Medical Devices and medical technologies – Bioinformatics • There are many opportunities in these areas, in general require shorter development and maturation time and are less capital intensive and still have good exit options, therefore representing a good option to balance the portfolio. • The new Fund will not invest in industrial biotech. 14 Cross Road Biotech SCR - Confidential Information
  15. 15. Timing for the incorporation of the Fund 15 2Q 3Q 4Q 1Q 2Q 2010 Venture Capital Investment Firm incorporation (CRB Inverbío) CRB Bio II Fund incorporation Fund raising 1st Fund closing 2nd Fund closing Ordinary operations 30/XII 2011 Cross Road Biotech SCR - Confidential Information 30/IV
  16. 16. Almagro 1, 1º derecha 28010 Madrid, Spain Tel.: +00 34 91 446 7897 Email: info@crbinverbio.com Web: www.crossroadbiotech.com
  1. Gostou de algum slide específico?

    Recortar slides é uma maneira fácil de colecionar informações para acessar mais tarde.

×